open access

Vol 61, No 3 (2010)
Original papers
Published online: 2010-07-02
Submitted: 2013-02-15
Get Citation

Potential benefits of hyperbaric oxygen therapy on atherosclerosis and glycaemic control in patients with diabetic foot

Nuri Karadurmus, Mustafa Sahin, Canturk Tasci, Ilkin Naharci, Cengiz Ozturk, Savas Ilbasmis, Zeki Dulkadir, Ahmet Sen, Kenan Saglam
Endokrynologia Polska 2010;61(3):275-279.

open access

Vol 61, No 3 (2010)
Original papers
Published online: 2010-07-02
Submitted: 2013-02-15

Abstract


Introduction: The aim of this study was to investigate the effects of hyperbaric oxygen therapy (HBOT) on glycaemic control, atherosclerosis, inflammatory markers, and other clinical and laboratory parameters in patients undergoing systemic HBOT for diabetic foot ulcerations.
Material and methods: Twenty-eight patients with Wagner grade 2-4 diabetic foot ulcerations were included. All patients were given 100% oxygen at 2.4 absolute atmosphere (ATA) for about 105 minutes, five times a week for a total of 30 sessions. Fasting blood glucose (FBG), haemoglobin A1c (HbA1c), homeostasis model measurement-insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hs-CRP), uric acid, mean platelet volume (MPV), complete blood count, and lipid profile were tested.
Results: Upon completion of treatment, a statistically significant improvement was observed in the mean values of all assessed parameters.
Conclusions: HBOT was shown to have beneficial effects on atherosclerosis and glycaemic control in diabetic patients. Further large-scale randomized studies are needed to study the systemic effects of HBOT.
(Pol J Endocrinol 2010; 61 (3): 275-279)

Abstract


Introduction: The aim of this study was to investigate the effects of hyperbaric oxygen therapy (HBOT) on glycaemic control, atherosclerosis, inflammatory markers, and other clinical and laboratory parameters in patients undergoing systemic HBOT for diabetic foot ulcerations.
Material and methods: Twenty-eight patients with Wagner grade 2-4 diabetic foot ulcerations were included. All patients were given 100% oxygen at 2.4 absolute atmosphere (ATA) for about 105 minutes, five times a week for a total of 30 sessions. Fasting blood glucose (FBG), haemoglobin A1c (HbA1c), homeostasis model measurement-insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hs-CRP), uric acid, mean platelet volume (MPV), complete blood count, and lipid profile were tested.
Results: Upon completion of treatment, a statistically significant improvement was observed in the mean values of all assessed parameters.
Conclusions: HBOT was shown to have beneficial effects on atherosclerosis and glycaemic control in diabetic patients. Further large-scale randomized studies are needed to study the systemic effects of HBOT.
(Pol J Endocrinol 2010; 61 (3): 275-279)
Get Citation

Keywords

hyperbaric oxygen therapy; diabetes; diabetic foot; atherosclerosis; glycaemic control

About this article
Title

Potential benefits of hyperbaric oxygen therapy on atherosclerosis and glycaemic control in patients with diabetic foot

Journal

Endokrynologia Polska

Issue

Vol 61, No 3 (2010)

Pages

275-279

Published online

2010-07-02

Bibliographic record

Endokrynologia Polska 2010;61(3):275-279.

Keywords

hyperbaric oxygen therapy
diabetes
diabetic foot
atherosclerosis
glycaemic control

Authors

Nuri Karadurmus
Mustafa Sahin
Canturk Tasci
Ilkin Naharci
Cengiz Ozturk
Savas Ilbasmis
Zeki Dulkadir
Ahmet Sen
Kenan Saglam

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl